ClinicalTrials.gg

Program

igrelimogene litadenorepvec

Its studies are mostly in Melanoma · Adenoviridae Infections · Lung Neoplasms, led by TILT Biotherapeutics.

Furthest: phase 2, since Feb 4, 20226 company-led studies, 4 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TILT Biotherapeutics64 open or runningphase 2since Feb 4, 2022Dec 19, 2019Nov 2026phase 1 · NCT06961786

Also a collaborator on its studies: Merck.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 19, 2019First study: phase 1 study in MelanomaFirst studyNCT04217473 · 17 enrolled · Denmark, France
  2. Jan 4, 2021Phase 1 study in Adenoviridae InfectionsNCT04695327 · 32 enrolled · Finland
  3. Feb 1, 2022Phase 1 study in MelanomaNCT05222932 · 15 enrolled · United States, Finland
  4. Feb 4, 2022Phase 2 study in Adenoviridae InfectionsNCT05271318 · 29 enrolled · United States, Finland
  5. Oct 31, 2023Phase 1 study in Lung NeoplasmsNCT06125197 · 22 enrolled · United States
  6. Apr 23, 2025Phase 1 study in MelanomaNCT06961786 · 9 enrolled · Denmark

Ahead

  1. Nov 2026Primary completion: phase 1 study in MelanomaNCT06961786
  2. Dec 2026Primary completion: phase 1 study in MelanomaNCT05222932
  3. Mar 2027Primary completion: phase 2 study in Adenoviridae InfectionsNCT05271318

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06961786Melanoma · Denmark1Active, not recruitingNov 20269
NCT06125197Lung Neoplasms · United States1Active, not recruitingJan 30, 202622
NCT05271318Adenoviridae Infections · United States, Finland2Active, not recruitingMar 202729
NCT05222932Melanoma · United States, Finland1Active, not recruitingDec 202615
NCT04695327Adenoviridae Infections · Finland1CompletedSep 3, 202532
NCT04217473Melanoma · Denmark, France1CompletedDec 12, 202317

How it is read

Names in the registry

  • “TILT-123”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.